Why Amgen Is Buying Onyx for $10.4B

Why Amgen Is Buying Onyx for $10.4B Play

Aug. 26 (Bloomberg) -- Amgen agreed to buy Onyx Pharmaceuticals in a $10.4 billion transaction that gives Amgen access to a rapidly expanding cancer-drug market with a new product that offers sure revenue. Olivia Sterns reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

  • On Air Now

    Charlie Rose Watch Now

  • Next

    Bloomberg West

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus